Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21372045 | 0.86 | ALDH1A1 (0.59) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL23188727 | 0.80 | ALDH1A1 (0.59) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL13618229 | 0.78 | LMNA (1.00) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL21675467 | 0.77 | ALDH1A1 (0.35) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL22704580 | 0.72 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPT | |
| SCHEMBL26556221 | 0.72 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL23921277 | 0.72 | ALDH1A1 (0.56) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL21515841 | 0.72 | ALDH1A1 (0.69) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL22946649 | 0.70 | ALDH1A1 (0.56) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL21511160 | 0.69 | ALDH1A1 (0.52) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI SHENZHEN (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | ALDH1A1 4610/4885LMNA 659/4885PI4KA 2386/4885 |
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | NT5C3B, NT5E, NT5C2 | ALDH1A1 1758/4885LMNA 559/4885PI4KA 1339/4885 |
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | GJA1, GAP43, GJB2 | ALDH1A1 4308/4885LMNA 1520/4885PI4KA 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.